Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.
Sec. Drugs Outcomes Research and Policies
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1340554

Analysis of criteria for choosing a drug treatment strategies for allergic rhinitis

Provisionally accepted
Damian Grzegorzewski Damian Grzegorzewski 1,2Marharyta Sobczak Marharyta Sobczak 2Michał Tołkacz Michał Tołkacz 3Rafał Pawliczak Rafał Pawliczak 2*
  • 1 Aurovitas Pharma Poland Ltd, Warsaw, Poland
  • 2 Department of Immunopathology, Medical University of Lodz, Łódź, Łódź, Poland
  • 3 Independent researcher, Lodz, Poland

The final, formatted version of the article will be published soon.

    Background: Allergic rhinitis is the most common type of rhinitis, treatment of which relies on relief of symptoms. Therefore, we aimed to assess the criteria, which influence doctors’ decision-making in the process of drug selection for the treatment of allergic rhinitis based on quantitative, qualitative and cost analysis Methods: We conducted a survey study with participation of 300 allergists. An in-house made questionnaire was presented during the computer assisted telephone interview (CATI) according to the standard procedures. Contingency table underwent statistical analysis using the Chi-Square Test with Cramer's v. Results were considered statistically significant at p<0.05. Results: Our analyses showed that doctors most often prescribe intranasal glucocorticoids and oral antihistamines to treat allergic rhinitis in patients of all ages. The most common factor, which affect the decision making related to AR treatment was efficiency of drug. We found the significant relationship between factors and main workplace (X-squared = 122.81, df = 90, p-value = 0.0123, Cramer’s V = 0.1787216), as well as voivodship of main workplace (X-squared = 440.75, df = 270, p-value = 2.378e-10, Cramer’s V = 0.1954731). In our study, respondents claimed that patients are willing to pay monthly 31-50 PLN (~ €7- €11) for treatment of allergic rhinitis with mild and moderate form; while 51-100 PLN (~ €11 - €22) in severe form. Conclusion: Our study confirms that management of AR should be focused on the patient. One of the most important factors in choosing a drug is its effectiveness. Moreover, an important factor in the effective treatment of AR is the financial issue, as our analysis shows, AR treatment costs can be a significant burden, especially for less wealthy citizens in Poland.

    Keywords: allergic rhinitis, Treatment, decision-making, cost analysis, allergic rhinitis therapy

    Received: 12 Mar 2024; Accepted: 02 Sep 2024.

    Copyright: © 2024 Grzegorzewski, Sobczak, Tołkacz and Pawliczak. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Rafał Pawliczak, Department of Immunopathology, Medical University of Lodz, Łódź, 90-419, Łódź, Poland

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.